-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 JT0Lf8CmdSMOU/xbe4bOsu7KRUkNQw5Yv6vgu8b5Xw7kKo4IBSbojWmSEirtCUfs
 7G6J/v/9EbZaUzu/gelnuA==

<SEC-DOCUMENT>0001193125-10-266275.txt : 20101122
<SEC-HEADER>0001193125-10-266275.hdr.sgml : 20101122
<ACCEPTANCE-DATETIME>20101122150808
ACCESSION NUMBER:		0001193125-10-266275
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20101117
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101122
DATE AS OF CHANGE:		20101122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AP PHARMA INC /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		101208440

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported) November&nbsp;17, 2010 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>A.P. Pharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-33221</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-2875566</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>123 Saginaw Drive</B> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redwood City, CA 94063 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(650)&nbsp;366-2626
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Registrant&#146;s telephone number, including area code </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;3.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;17, 2010, A.P. Pharma (the &#147;Company&#148;) received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market
(&#147;NASDAQ&#148;) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company&#146;s common stock to be $1.00 or more. This second notice states that the Company&#146;s
securities would be subject to delisting from The NASDAQ Stock Market, effective November&nbsp;29, 2010, unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel (&#147;Panel&#148;). A.P. Pharma intends to request a hearing
before the Panel. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing description is qualified in its entirety by reference to our press release dated November&nbsp;22, 2010, a
copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:76pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Document Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release issued on November 22, 2010.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: November&nbsp;22, 2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>OHN</SMALL> B.
W<SMALL>HELAN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>John B. Whelan</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Acting&nbsp;Chief Executive Officer and Chief Financial Officer</B></FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:2%">

<IMG SRC="g121978g49c06.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For Immediate Release </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma Receives Second Letter from NASDAQ Regarding </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notice of Non-Compliance;
Company to Request Hearing </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REDWOOD CITY, Calif.</B> &#150; November&nbsp;22, 2010 &#150; A.P. Pharma, Inc. (NASDAQ: APPA), a specialty
pharmaceutical company, today announced that, on November&nbsp;17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule
5550(a)(2), which requires the closing bid price of the Company&#146;s common stock to be $1.00 or more. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This letter is a follow-up to the
letter received from NASDAQ on May&nbsp;18, 2010, which notified the company that it was out of compliance with Listing Rule 5550(a)(2) because the bid price of its common stock had closed at less than $1.00 per share over the previous 30
consecutive business days. At that time, NASDAQ provided the Company with 180 calendar days, or until November&nbsp;15, 2010, to regain compliance with the rule. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The second letter from NASDAQ stated the Company&#146;s securities would be subject to delisting from The NASDAQ Stock Market, effective November&nbsp;29, 2010, unless the Company requests a hearing
before a NASDAQ Listing Qualifications Panel (Panel). A.P. Pharma intends to request a hearing before the Panel at which it will present its plan for regaining compliance with all applicable listing requirements. The hearing request will result in
the Company&#146;s shares remaining listed on The NASDAQ Capital Market at least until such time as the Panel renders its decision following the hearing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There can be no assurance that the Panel will grant the Company&#146;s request for continued listing on The NASDAQ Stock Market. In the event that the Panel determines to delist the Company&#146;s
securities from NASDAQ, the Company&#146;s common stock may be eligible for trading on the OTC Bulletin Board, which is operated by FINRA or the OTCQB, which is operated by OTC Markets, Inc. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>A.P. Pharma Receives Second Letter from NASDAQ</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Regarding Notice of Non-Compliance; Company to Request Hearing </I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> Page&nbsp;
 2
</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About A.P. Pharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer&#153; polymer-based drug delivery technology. The Company&#146;s primary focus is on its lead
product, APF530, for the prevention of CINV. A.P. Pharma received a Complete Response Letter on the APF530 NDA in March 2010 and is in the process of preparing a resubmission responsive to the deficiencies listed in the Complete Response Letter. The
Company has additional clinical and preclinical stage programs in the area of pain management, all of which utilize its bioerodible injectable and implantable delivery systems. Further work on these programs has been deferred while the Company
focuses on the approval of APF530. For further information, visit the Company&#146;s web site at <U>www.appharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-looking
Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This news release contains &#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of
1995. These forward-looking statements involve risks and uncertainties, including uncertainties associated with timely development, approval, launch and acceptance of new products, satisfactory completion of clinical studies, establishment of new
corporate alliances, progress in research and development programs and other risks and uncertainties identified in the Company&#146;s filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect
our analysis only on their stated date. We do not intend to update them except as required by law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Contact: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma, Inc.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan, Acting Chief Executive Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">and Chief Financial Officer 650-366-2626 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor and Media Relations: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate
Communications Alliance, LLC </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Edie DeVine </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">209-814-9564 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g121978g49c06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g121978g49c06.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`/`"S`P$1``(1`0,1`?_$`)\```("`P$!````````
M```````&`0<$!0@#`@$!``(#`0````````````````0%`0,&`A```0(%`P($
M`@@#!0D``````0(#`!$$!08A$@<Q$T%1(A2!"&%Q,D)28B,5L<&"D>&B1!=R
MPC-#8W,D%A@1``("`@$"!0,"!04````````!`@,1!`4Q$B%!42(384(4@3+P
M<;$S%9&AT>&B_]H`#`,!``(1`Q$`/P#JF`"`"`()UC&0+&1\E89CY4W<+B@U
M*?\`*L_JN_%*)R^,2J=.RSHB'?OU5=6(-P^9"TH64T%G??3/1;SB&ICZ@%F+
M"'"S?5X*VSG8+I')CL_,FWW$AVP*#?WBFH!5+Z`4`1L_P4L>$LGA<]'SB6!A
MO)^*94KL4+RF*\":J&H`0[(=2G4A4ORF*S9TK*O&70M-;?KN\(OQ&T1$)I,9
M`0`0`0`0`0`0`0`0`0`0`0`0`0`&`#6`-)E.86/&;<:ZZOAM!F&F4^IUU7X6
MT^)C=11.UXB:+]F%2S(Y]S;FC)\A6NGHEJM-K,P&65?K+3_U'!K\$QTFKQ4*
M_&7C(Y;;Y:RQXCX1*^)F23U/4^)^N+/"70JG)OJ0-(R"3(P;,(]:6JJ:2I9J
MJ1Q3-2PL.,O(,E)6GH08\65*:P_,]5V.#[EU.N\(R$Y#BUMNR@`[4M#OI'0.
MH)0O_$DQQ6S5\=DHG=ZEOR5J7T-[,QI)`$F`-/5Y?CE)>6K)4U[3=U?VAJD,
M]ZM_V>@\91LC3)Q[L>!IEL04NUOW&XF=(UF\F<#&2)F!DF9@")P`$F`)G&,@
M@DSC.03.,`-8R`G``3(1A@5<_P`\MN(VDU3X[]<]-%#1`^IQ?F?)(\3$K5U7
M=+"Z>9$V]R-,<^;Z%*U''G*N;5!OES:2TI_5A-6YVMJ#J$M-244)^L"+V.YK
MT+LB<[9I[.P^^7_`DY'C-ZQRXFW7>G[%3M#B)$*0M!GZD*&A&D6.O?&V.8E;
MLZ\ZI=LEXFJ.@/E&_)I2'BGX9SNIIJ&I9I65-7!*5MJ[H';0I.\*<F!MTBNE
MRM2;6?%?0L5Q-S2?J8N8<897BE(W6W%MIZB6H(-33KWI0L]`L$)4)^?2/>MR
M,+7VKJ:]KC;*8]SZ"E.43R`CI#C^]T6)\/T%VNN_VXWN;&P%+/>?(0$@D><X
MY';KE;LN,>IV.E:J=52E_'B>=7\PF%M--+88K*E;@FXTE"$EO60"RI0$SY`Q
M[CQ%N<-K_4Q+F:DLI,>,5RJT9/:47.UN%;*E%#B%C:M#B>J5#P(B!L42JEB1
M/UMB-L>Z)1M1E-F:YLN%^NSI%%;''$,)2DK4M;+?9;0A(\=Q)B_5$OQ%&/5G
M/O8BMMRET19&(<SX[DE\19VZ6IHJE[=[8OA)2LI!)2=I.U4A.*N_CIUP[NJ+
M36Y2%L^S&&;_`#+/<>Q*G;<NCJB^_/VU(T-SKDNLAH`->I,1M?5G<_:2MG<A
M2LR\Q2M?/5AJ;HQ0UULK+;[E:4-//A.V:S))4-"`3XZQ-GQ<E',9*6/0A1Y>
M'=VRBXY''-\RH,2LW[I6M./-EU#"6FMN\J7/IND-`(A:VM*Z?:B=M;4:8=S-
M!8>7[+?<@M]CMM*\Y55C1>J'"4A%.`C>4J/WU#H=NDXWVZ$ZX.4GX$:GDH63
M48KJ:^KYZQNFN=PM[E#5+<HUK:94WM7WW4+V[4`'3I.9C;'BK'%2RL,URY:M
M2<</*/"T?,'C=0[4MW6BJ+664E3>XATK4"!VY)"2%F>@,>Y\1-).+4D_T/-7
M,P;:DF@M?/5OK,AIK4_9ZFB9JW$M-OO*&\%PR05-RZ$^1C$^*DH.:DG@0Y>+
ML4.UK(ZYEFUFQ*V)KKH5GNJ[=.PTG<MQ<I[4]`/B8@ZVO*YX18;.S&E98A*Y
M]735+!NN-5E!0U)_2?69**)_:"5)2%2&I`,3UQ+:]LTV5CYC$EW0:BRUO=L_
MB_Y7>_H\XJNQEQWK_8\[W=Z*SVJJN=<OMTM(V7'5>,AX#Z2=!'JNMSDHKJS%
MMBA%R?1'*MUNN2Y[EY>8:6]75"I45,V9!EI!FD!71(3U4KSCK:ZX:U7C^IQM
MD[-JW,>ODBP4X7<ZK(K:G+<W2+T'&DT]MIUJ<=FB1"/24@%4M3MBKELP4)?'
M7[?4MXZTG9'Y+/=Z&G^8:X(J,RI*1'6CHTAP_F=65_P`B3PL7\;?U(?.27R)
M?0KBUT+E?<Z.A;$UU;[;*1_W%A/\XM;K%&#?HBIIAW32^I;OS`7ZJI:NU8_1
M5+C%*S3=ZH9;44!6H0T%;93D$'2*3B:%/NG(O.:O<>V"\/`]S5U1^79URZ.*
M=<>_3HU.DJ44FH`:U.IE(R^B-?:OS<0Z&R4F]',BH+!9:N^7JCM5(F;]6X&D
MG\*3]I1^A*=8OK[OC@Y/R*'7I^2:BO-ET\].4]HPNR8[2>EHN)"$#KVZ5N0_
MQ*$<_P`5'OME-^2R=#S#[*HUH:CCMBL?%KU-54C*6V;:I=62A,U/%J943UW;
MS$3YISV,I_<3%KPAKX:7[14X!=<M^$WZZ/S%,V\IQ,^GZ#`*R/X1-YC$K8Q\
MR'P^8TR9A_+_`&2FN57><BK6$//!U**=;B0HI6N;CBDSZ'U#6/?+V."C"+\,
M'CAZ8S<K)+QR>>/-HO7S!5U6RD!BWJ>5Z1(39;#$]/-2HQ<^S22?61BA?)NM
MI?M&?->0[.K(&K+:+$,ER&A65-#:"VPX!(^J1,Q/7P'G$36TY*'?*79!DO;V
MX.SL4>^:*]RFJR[).1+#:LBHV*&M0XR$4U.=VUIUP.'>K<K7:CX19T*NJB4J
MWF)57NVW8C&:28S_`#%5SCZ[#9&3-U]Q;Q0/,D--Z?6HQ$X:..Z?H3.;GGMA
MZE@6S&,;PK&GGZ*D;;=H:5QUZJ(!=6I"-RB7#KJ1%=.ZRZ:R^K+.&O73!M+&
M$5Y\O%H:J?WC(*II*ZA3R6675@$I)!<=*2>DRL19<Q8X]L%Z%9PU2EW3:,3C
MFDI<DY?OMY>:0[34JGW60I(4D++@:;5(Z3VI)C9NS=>K".?%GG1@K-J<L>"/
MO($C(/F!H:-("F+:II+GE_X[9?5/^I0$8I?QZ3?J8NQ9NI+[1MSSD>EI[PWB
M]JLXR"_%25^V6`6FEI]:2KK-2?M:=/$Q"U=)N'R3EVP)VWNI3^.$>Z16?)M7
MR!<KE:+/E"*5A^H6':.CI-2CNK#4UJFKX:Q:Z,:(0G.#?@O,JM^5TIPA-+Q]
M#HOV(_%_E^Q_?'.]_P#7)TW9_3!3_P`Q>1K;IK?CS*I"H)JZL#Q0@[6TG^J9
M^$7'"T9;F_Y%'SNQA*"%7@_*,<L%\KG+T\BE54L);I:IP>A,E$K03X;M/[(E
M\M5.R*[?(@\-?"N;<C>8^OB.P9DJ[.Y`]<Z]3CK[=6I!]NR5S^VM(FXN2I"(
MMRVK*NWM[43*IZM=O<YN3-`+QAE]Y7N=TR-]"\?5W.PI8<V.A"4MM#T>KS5$
MEU75ZZC7^\B?+59L.5C]ADX;06"Z\TM?L#*6['1K54TR4;BDI8:EN]<SZG3X
MQYV93AJ>]^YGO5C">Y[/V(8LT3Q'?\JK*B^W:IH*^W+]I54^NQY+/3MR2OSE
MZ=8B:KV:Z_9'*9,V_P`6VS,Y8<1>R/D'&[_?K)90W[/![4\A3J%I5^LEM,A-
M"9JV_=2.NL2Z=*RN$IO^ZR'?NUVSC!?VD7'C>#8G;KB+[:*%%(7Z=+;*$H+>
MU"CN4HI5ZMRM`9^`BDMVK)+MD\E]5J51EWQ6"K>9DUM_Y+M./T"DBH990EHK
M^REUY1<FKKH$I$XMN-Q71*<NA3\IFS8C"/4S;K9>;LN918;NS3V^VI4GW54D
MH"7`DZ$A"E*7Y[0`/.-<+-2KWQRY^AMLIV[EV36(^H\7G#JFV\9U6,XTSWJE
M;'81N4E"EEQ0[KBE*($R"8@U["G>IV=,D^W6<*'"OJ'%>*7+&,+%%6,A-S6X
M\^ZT%)4-Q,D)W`R^RD1G>OC;=W)^TQH:\J:<?<:/A_`LCL-TO5UO["&:JNDE
MG:XEPD*6IQPDI)EZI1MY#;C9&,8]$:>/TYUSE*?60M63!.6L8RBY5-DIZ5_W
MQ6@UU0M!04*<*PJ4PL*\Q*)5NWKVUQ4F\Q(=6ILU6MP2]WF;;$N-<WI^2D9%
MDCK5:AL.*-:A8FIPM[$2;D"E*9D"-6SO5.CXZU@WZ^A:K_DL>3/RC`,EOG*=
MMO3C;7[#;RQ)9<&\AHEPR1+\9C51M0AKN'W,V;&G.S94_M0X<@VJ\7;$+C;+
M2E"JVL0&DAQ>Q(0I0W^J1^[.(FI9&%D92Z(G[E<IU2C'JS58!B-WQG`5VQ26
M_P!Y6*AW:E4T=YR8;]<N@`3&[<V8VW=WVFC3UI54]OW&!P[Q_>,4I;DY>$M"
MMK7$;>TON#MM@G4R&I4HQZY':A:UV]$:N,TYTJ7=U9C8+QYD5NY`N^3WKL[:
MOO>U[;F]4WG`?4"D2DA,H];.Y&5,:X^74\ZNG.-\K)>?0T]PXVY(MN?UV18T
M_2$5KCBTOU"A-"'I%2%((,Y2T(B1#=HE2J[$_`TST;XWNRMKQ/2CXGSAS.[=
M?[[<F+HU3N-O5#I*DJ!0"0AMO;M"4JZ=(\RY"I4N$(XR(\=<[E9-YP7'(^?A
M%-@O3FGGQ3QY!7W)[$TC`:_V?43+^J<=3PO]G]3D.;S\WZ%<1;%023'K(R`C
M&0-W&V=4N&W2JN#M"JN=?8#+82L(V#=N43,'K(17[VF[DDGC!8<?N*AN361:
MK:BHN-R?JB"NHK7UN!"9J45NJ*MH`U)UE$N"4()>A$G)V3;2ZEV<3\-&D=8O
MV2M#W29.45M5J&SU#CWYAX)\(H.0Y/N]D.GJ='QW%]OOGU]"Z`)11E[@0J3C
M)Q')+N95-P#^XK+5'VR-DV^TCU[C/:GZ(L'O9H^)(KXZ&+_E;'W:(@%B`2!`
MQ@F4#)$HQ@!M@D8)E&3(2$`$H`)0`2C``"&`$HR`E&,`)1D8*DYVX_KKS24]
M^M;2GJR@06ZJG0)K6Q/<%)'B4&>GE%OQ.VJVXR>(LI>7TW9%2BLR1SX00=1(
MSD1Y$1T\9)K*.4:><$3C)@G^?2!F*R-N*\79CDBT*I:,TM$HZUU4"VW*?5((
MW+^`BOV.1KK\.OT)^MQMMOEA%\8+Q+CV*A-3M]_=I>JN>`]/T-(U"/XQSVWR
M$[GZ1]#IM/CJZ5GK(>)1`+`F,@B6L!@F`"`"`"`"`"`"`"`"`"`"`"`"`"`(
M5TC#!5V>?Z(>[<_?_;_N<_U/:;_<3_-V/]Z+34_)^S."IV_Q/OQD34__`#CN
M$_>R\9^ZE\8G2_._C!7K_'_7_P!#_AW^BO=1_P"O_M_N]-G=_P"//Z._ZI_5
M%?L_D_?G^/Y%CJ?B?9C]?^RPT2TET\)17(M#Z@9"`"`"`"`"`"`"`"`"`"`"
,`"`"`"`"`"`"`/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
